Analysed KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS) News Sources
Assessing Kaken Pharmaceutical’s (TSE:4521) Valuation After Recent Muted Share Price Momentum
27-03-2026
yahoo.com
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
25-03-2026
yahoo.com
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
22-12-2025
yahoo.com
Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)
13-11-2025
yahoo.com
Evaluating Kaken Pharmaceutical (TSE:4521): Is the Current Valuation Supported by Fundamentals?
14-09-2025
yahoo.com
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
12-08-2025
yahoo.com
Astria Therapeutics licenses navenibart rights to Kaken for HAE
07-08-2025
pharmaceutical-technology.com
What is the current price of KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS)?
The current price of KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS) is $0.
KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS) since the previous trading day is $None.
KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS) since the previous trading day is None%.
What is the most recent average sentiment score for KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS)?
The most recent average sentiment score for KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS) is 67 out of 100.
What is the most recent average sentiment for KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS)?
The most recent sentiment for KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS) is .
SEC-8K** Filing Available For KAKEN PHARMACEUTICAL CO LTD (KKPCF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.